6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carbaldehyde | 1602486-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carbaldehyde
• 英文别名: 6-Chloro-4-(4-methyl-3-nitroanilino)quinoline-3-carbaldehyde
• CAS: 1602486-39-4
• 化学式: C₁₇H₁₂ClN₃O₃
• 分子量: 341.754
• InChiKey: STMXAOAYECTBCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carbaldehyde 在 tin(II) chloride dihdyrate 、 bis(triphenylphosphine)palladium(II) dichloride 、 sodium carbonate 、 potassium carbonate 、 三乙胺 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 20.17h， 生成 BMX-IN-1
  参考文献：
  名称：

  [EN] BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE KINASE MOELLE OSSEUSE SUR CHROMOSOME X (BMX) ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014063054A8
• 作为产物：
  描述：

  ethyl 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carboxylate 在 manganese(IV) oxide 、 sodium tetrahydroborate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carbaldehyde
  参考文献：
  名称：

  [EN] BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE KINASE MOELLE OSSEUSE SUR CHROMOSOME X (BMX) ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014063054A8

文献信息

• Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10000483B2

  公开（公告）日：2018-06-19

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.

  本发明提供了新颖的式(I)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同系物、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及式（I）或（II）化合物或其组合物的方法和试剂盒，用于治疗或预防受试者的多种疾病（如增殖性疾病（如癌症、良性肿瘤、血管生成、炎症性疾病、自身免疫性疾病）和代谢性疾病（如糖尿病（如 2 型糖尿病、妊娠糖尿病））。使用式(I)或(II)化合物或其组合物治疗患有疾病的受试者，可下调激酶（如酪氨酸激酶，如Tec激酶，特别是X染色体上的骨髓激酶（BMX））的表达和/或抑制其活性，从而抑制受试者体内的酪氨酸激酶单体。
• Structure–Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent
  作者：Yanke Liang、Melissanne de Wispelaere、Margot Carocci、Qingsong Liu、Jinhua Wang、Priscilla L. Yang、Nathanael S. Gray

  DOI：10.1021/acsmedchemlett.7b00008

  日期：2017.3.9

  Here we report the structure activity relationship (SAR) investigations of QL-XII-47 (QL47), a compound that possesses broad-spectrum antiviral activity against dengue virus and other RNA viruses. A medicinal chemistry campaign initiated from QL47, a previously reported covalent BTK inhibitor, to derive YKL-04-085, which is devoid of any kinase activity when screened against a panel of 468 kinases and with improved pharmacokinetic properties. Both QL47 and YKL-04-085 are potent inhibitors of viral translation and exhibit cellular antiviral activity at 35-fold lower concentrations relative to inhibition of host-cell proliferation.
• BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20150246913A1

  公开（公告）日：2015-09-03

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.